Exenatide
Synthetic version of exendin-4 from Gila monster saliva. First-in-class GLP-1 receptor agonist (twice-daily Byetta and weekly Bydureon).
FDA-approved 2005 (Byetta) and 2012 (Bydureon). Pioneered the GLP-1 class. Less weight-loss potency than later analogs but well-characterized 20-year safety record.
Older class member; rarely first-line in 2025. Twice-daily Byetta has injection-burden compliance issues. Same class watches.
Known risk or pharmacological conflict.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- BModerate evidence
Exenatide — primary mechanism: synthetic version of exendin-4 from gila monster saliva. first-in-class glp-1 receptor agonist (twice-daily byetta and weekly bydureon).
1 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 5-10 µg twice daily or 2 mg weekly · varies by formulation, subcutaneous
Draw volume is below 5 units — hard to measure accurately on most syringes. Consider adding more BAC water to dilute, or moving to a smaller syringe.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
FDA approved (Byetta / Bydureon)